Some of the most wanted therapeutic drug targets are still considered undruggable. The cutting edge research of Ambagon’s scientific founders has identified a way to solve this challenge through the use of “molecular glues” that stabilize native interactions of the 14-3-3 regulatory proteins. Ambagon’s technology has platform potential and is applicable in a variety of indications beyond cancer.
Company: Ambagon Therapeutics
Ambagon Therapeutics applies deep knowledge of the 14-3-3 regulatory protein famiy to create “molecular glues” that stabilize 14-3-3:target complexes. These stabilizers amplify native biology to restore or inhibit target function, potentiate target activity, or promote or block target degradation.